Rocket Pharmaceuticals officer proposes $9.2K sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Rocket Pharmaceuticals, Inc. officer Martin Wilson reported a proposed sale of 4,087 common shares for an aggregate market value of $9,196.98, with an approximate sale date of November 13, 2026. The 4,087 shares were acquired from the issuer on November 11, 2026, through restricted stock vesting as compensation. The notice says the proposed sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution.
Key Figures
Key Terms
Restricted Stock Vesting financial
vested equity award distribution financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What earlier RCKT sales are listed for Martin Wilson?
AI-generated analysis. How Rhea-AI works. Not financial advice.